Hospital
Scripps Health
Scripps Health was paid $64.23M by Medicaid between Jan 2018 and Dec 2024, across 338 billing codes. Its largest line is 0450, Emergency room services — 11% of everything it billed.
33Billing provider infoSCRIPPS HEALTH
SAN DIEGO, CA 92103
SAN DIEGO, CA 92103
33aNPI1659359446assigned 01/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$64.23M
24GClaims1,854,550
24DCodes billed338
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#45 of 410
Median peer was paid$6.90M
This provider vs. median9.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 351,673 | $10.37M | |
| 2019 | 289,276 | $9.70M | |
| 2020 | 210,315 | $7.01M | |
| 2021 | 239,442 | $8.41M | |
| 2022 | 293,999 | $10.61M | |
| 2023 | 275,684 | $10.63M | |
| 2024incomplete | 194,161 | $7.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 11% | 113,593 | 99,994 | $7.26M |
| 99499 | 11% | 40,892 | 31,526 | $7.02M | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.1% | 90,223 | 87,154 | $5.87M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.9% | 56,496 | 52,831 | $3.81M |
| 0762 | 3.7% | 1,198 | 1,124 | $2.40M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.5% | 86,107 | 80,577 | $2.28M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.5% | 14,350 | 14,168 | $2.23M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 17,103 | 16,144 | $2.21M |
| Z7502 | 3.1% | 52,902 | 51,959 | $1.97M | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 11,998 | 10,954 | $1.97M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 6,763 | 6,195 | $1.54M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.2% | 13,277 | 12,447 | $1.41M |
326 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 30,780 | $1.28M |
| 80053 | Comprehensive metabolic panel | 2.0% | 108,280 | $1.27M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 145,694 | $1.04M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 12,991 | $995K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 7,609 | $989K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 14,262 | $876K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 4,932 | $787K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 14,342 | $711K |
| A4217 | Sterile water/saline, 500 ml | 1.0% | 53,087 | $667K |
| 0360 | <1% | 4,535 | $610K | |
| 71045 | Radiologic examination, chest; single view | <1% | 42,025 | $591K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,916 | $460K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,806 | $432K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 6,733 | $426K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,828 | $400K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,060 | $362K |
| 84484 | <1% | 38,692 | $359K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,315 | $349K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,583 | $343K |
| J3490 | Unclassified drugs | <1% | 175,698 | $330K |
| 70486 | <1% | 1,966 | $298K | |
| 83690 | <1% | 41,639 | $291K | |
| 76801 | <1% | 4,235 | $290K | |
| 71250 | <1% | 2,266 | $264K | |
| 72131 | <1% | 1,590 | $218K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,399 | $216K |
| 83880 | <1% | 9,733 | $212K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,024 | $210K |
| 70496 | <1% | 923 | $202K | |
| 93975 | <1% | 1,036 | $196K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,840 | $196K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 23,120 | $194K |
| 0710 | <1% | 4,049 | $190K | |
| 0720 | <1% | 5,147 | $183K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,618 | $181K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,257 | $178K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,133 | $172K |
| 76830 | Ultrasound, transvaginal | <1% | 2,488 | $171K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,465 | $163K |
| 70498 | <1% | 853 | $161K | |
| 99199 | Unlisted special service, procedure or report | <1% | 3,458 | $161K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,509 | $161K |
| 93971 | <1% | 1,717 | $156K | |
| 93970 | <1% | 952 | $155K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 933 | $151K |
| 80306 | <1% | 6,293 | $148K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,363 | $147K |
| 90715 | <1% | 3,512 | $147K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,512 | $143K |
| 0510 | <1% | 4,760 | $134K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,125 | $132K |
| 59025 | Fetal non-stress test | <1% | 6,974 | $123K |
| 72128 | <1% | 903 | $121K | |
| Z7610 | <1% | 20,057 | $119K | |
| 81001 | <1% | 36,748 | $112K | |
| 73630 | <1% | 3,707 | $109K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,110 | $107K |
| 73130 | <1% | 3,085 | $102K | |
| 0270 | <1% | 13,500 | $101K | |
| 73610 | <1% | 3,060 | $97K | |
| 73562 | <1% | 3,421 | $96K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,089 | $95K |
| 77066 | Tomosynthesis, mammo | <1% | 694 | $92K |
| 73030 | <1% | 2,962 | $91K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 820 | $85K |
| 93976 | <1% | 431 | $82K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,490 | $80K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,500 | $80K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 352 | $78K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,851 | $77K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 491 | $76K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,013 | $74K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,342 | $73K |
| 96379 | <1% | 4,683 | $71K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 308 | $67K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,937 | $66K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,737 | $63K |
| 73110 | <1% | 2,017 | $63K | |
| 83605 | <1% | 7,053 | $62K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 978 | $61K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,478 | $59K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,591 | $58K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 856 | $57K |
| 72100 | <1% | 1,785 | $55K | |
| 87040 | <1% | 4,131 | $54K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,265 | $53K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,314 | $51K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,000 | $49K |
| 85730 | <1% | 10,479 | $49K | |
| 0259 | <1% | 10,874 | $47K | |
| 85610 | <1% | 15,101 | $47K | |
| 97139 | <1% | 1,397 | $45K | |
| 84703 | <1% | 7,916 | $44K | |
| 73502 | <1% | 1,461 | $43K | |
| 81025 | <1% | 7,012 | $43K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,977 | $42K |
| 84702 | <1% | 3,172 | $42K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,883 | $42K |
| 94060 | <1% | 951 | $42K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,836 | $39K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,961 | $39K |
| 29125 | <1% | 983 | $38K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,108 | $37K |
| 76641 | <1% | 513 | $36K | |
| 73590 | <1% | 1,420 | $35K | |
| 83735 | <1% | 7,238 | $34K | |
| 77065 | Tomosynthesis, mammo | <1% | 301 | $31K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,686 | $29K |
| 86900 | <1% | 4,241 | $29K | |
| 87077 | <1% | 4,447 | $29K | |
| 87186 | <1% | 4,042 | $28K | |
| 0750 | <1% | 186 | $28K | |
| 94644 | <1% | 1,209 | $28K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,148 | $26K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 385 | $26K |
| 94729 | <1% | 807 | $25K | |
| 73080 | <1% | 851 | $25K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,455 | $25K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 916 | $24K |
| 76642 | <1% | 430 | $24K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,493 | $24K |
| 10060 | <1% | 492 | $23K | |
| 73090 | <1% | 854 | $22K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,804 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,763 | $22K |
| 0258 | <1% | 2,262 | $21K | |
| 72040 | <1% | 784 | $21K | |
| 81003 | <1% | 9,386 | $21K | |
| 29515 | <1% | 443 | $21K | |
| 85379 | <1% | 2,189 | $21K | |
| 12001 | <1% | 542 | $20K | |
| 12002 | <1% | 238 | $19K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 684 | $19K |
| 77080 | <1% | 350 | $18K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 347 | $18K |
| 74022 | <1% | 437 | $18K | |
| 0760 | <1% | 468 | $18K | |
| 97750 | <1% | 349 | $18K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 98 | $17K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 30 | $16K |
| 82805 | <1% | 804 | $15K | |
| 86901 | <1% | 4,344 | $15K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 350 | $15K |
| 78264 | <1% | 38 | $15K | |
| 82803 | <1% | 1,494 | $14K | |
| 97161 | <1% | 685 | $14K | |
| 86850 | <1% | 2,644 | $14K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 324 | $13K |
| 10061 | <1% | 405 | $13K | |
| 86140 | <1% | 3,338 | $13K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 55 | $13K |
| 88304 | <1% | 1,058 | $12K | |
| 94726 | <1% | 460 | $12K | |
| 93308 | <1% | 164 | $12K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 155 | $12K |
| 0250 | <1% | 2,363 | $12K | |
| 87631 | <1% | 184 | $12K | |
| 87210 | <1% | 1,848 | $11K | |
| 82550 | <1% | 2,113 | $11K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,371 | $11K |
| 76813 | <1% | 148 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 268 | $11K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 469 | $11K |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 136 | $10K |
| 73060 | <1% | 457 | $10K | |
| 0272 | <1% | 7,115 | $9K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 614 | $9K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 39 | $9K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 27 | $9K |
| 73552 | <1% | 364 | $8K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 373 | $8K |
| 71020 | <1% | 276 | $8K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $8K |
| 76870 | <1% | 150 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 535 | $8K |
| 97799 | <1% | 260 | $8K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 177 | $7K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,071 | $7K |
| 0160 | <1% | 60 | $7K | |
| 82330 | <1% | 700 | $7K | |
| 90686 | <1% | 231 | $7K | |
| 74018 | <1% | 289 | $7K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 87 | $6K |
| 0681 | <1% | 44 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,612 | $6K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $6K |
| 12011 | <1% | 196 | $6K | |
| 87070 | <1% | 993 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,315 | $6K |
| 72170 | <1% | 289 | $6K | |
| 93798 | <1% | 358 | $6K | |
| 94727 | <1% | 187 | $5K | |
| 87081 | <1% | 743 | $5K | |
| 0370 | <1% | 799 | $5K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 408 | $5K |
| Z7500 | <1% | 143 | $5K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 30 | $4K |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 90 | $4K |
| 85652 | <1% | 2,548 | $4K | |
| 97116 | <1% | 643 | $4K | |
| 76770 | <1% | 69 | $4K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 334 | $4K |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 82 | $4K |
| 99070 | <1% | 1,247 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 84 | $4K |
| J0897 | Injection, denosumab, 1 mg | <1% | 20 | $4K |
| 72070 | <1% | 124 | $4K | |
| 76604 | <1% | 129 | $4K | |
| 70491 | <1% | 17 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 359 | $3K |
| 87205 | <1% | 1,230 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 509 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 975 | $3K |
| 71010 | <1% | 168 | $3K | |
| 97165 | <1% | 157 | $3K | |
| 51702 | <1% | 45 | $3K | |
| 95812 | <1% | 38 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 378 | $3K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 28 | $3K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $3K |
| 84145 | <1% | 208 | $2K | |
| 73140 | <1% | 134 | $2K | |
| 36600 | <1% | 314 | $2K | |
| 80061 | Lipid panel | <1% | 3,194 | $2K |
| 70490 | <1% | 13 | $2K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,360 | $2K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,668 | $2K |
| 82140 | <1% | 173 | $2K | |
| L4361 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 16 | $2K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 73 | $2K |
| 82010 | <1% | 318 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 492 | $2K |
| 82570 | <1% | 1,988 | $2K | |
| 71101 | <1% | 56 | $2K | |
| 97162 | <1% | 92 | $2K | |
| 93017 | <1% | 57 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 146 | $2K |
| 76536 | <1% | 30 | $2K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $2K |
| 82553 | <1% | 198 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 234 | $2K |
| 96376 | <1% | 138 | $2K | |
| G0378 | Hospital observation service, per hour | <1% | 29 | $2K |
| 73560 | <1% | 91 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 87 | $2K |
| 0320 | <1% | 32 | $1K | |
| 90632 | <1% | 32 | $1K | |
| 80051 | <1% | 279 | $1K | |
| 85018 | <1% | 730 | $1K | |
| 12013 | <1% | 19 | $1K | |
| 93356 | <1% | 55 | $1K | |
| 84100 | <1% | 871 | $1K | |
| 96367 | <1% | 25 | $1K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 50 | $1K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 24 | $1K |
| 74220 | <1% | 31 | $1K | |
| 62270 | <1% | 13 | $1K | |
| 29505 | <1% | 13 | $1K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 40 | $1K |
| 85014 | <1% | 469 | $1K | |
| 82947 | <1% | 229 | $923.55 | |
| 84439 | <1% | 867 | $919.39 | |
| 86780 | <1% | 55 | $914.07 | |
| 84156 | <1% | 535 | $881.55 | |
| 82248 | <1% | 215 | $871.17 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 38 | $864.65 |
| 82728 | <1% | 692 | $855.59 | |
| 92611 | <1% | 27 | $844.17 | |
| 87505 | <1% | 15 | $728.78 | |
| 87147 | <1% | 81 | $689.75 | |
| 76775 | <1% | 13 | $680.12 | |
| 84550 | <1% | 220 | $663.73 | |
| 80074 | <1% | 14 | $549.56 | |
| C1769 | Guide wire | <1% | 252 | $515.24 |
| 85027 | <1% | 121 | $512.55 | |
| 82607 | <1% | 396 | $508.34 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 15 | $506.30 |
| 82375 | <1% | 90 | $491.24 | |
| 80164 | <1% | 39 | $489.64 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 75 | $450.96 |
| 73564 | <1% | 14 | $444.65 | |
| 74230 | <1% | 13 | $442.32 | |
| 0301 | <1% | 18 | $435.76 | |
| 82950 | <1% | 110 | $431.05 | |
| 72072 | <1% | 12 | $382.98 | |
| 96368 | <1% | 14 | $373.87 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 26 | $369.88 |
| 70360 | <1% | 27 | $369.58 | |
| 97166 | <1% | 16 | $369.10 | |
| 84466 | <1% | 623 | $367.76 | |
| 83540 | <1% | 709 | $338.79 | |
| 88307 | <1% | 13 | $328.10 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 45 | $312.10 |
| 82043 | <1% | 1,087 | $282.20 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $282.18 |
| 87449 | <1% | 18 | $272.55 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 12 | $252.05 |
| 80185 | <1% | 31 | $244.70 | |
| 83050 | <1% | 61 | $213.80 | |
| 83970 | <1% | 169 | $207.64 | |
| 84132 | <1% | 61 | $203.29 | |
| 0255 | <1% | 16 | $197.36 | |
| 88342 | <1% | 13 | $163.97 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 102 | $128.36 |
| 88300 | <1% | 41 | $113.62 | |
| 94760 | <1% | 81 | $110.99 | |
| 87075 | <1% | 12 | $95.11 | |
| 0379 | <1% | 277 | $88.62 | |
| 87340 | <1% | 90 | $72.10 | |
| 86308 | <1% | 15 | $66.77 | |
| 82247 | <1% | 16 | $56.68 | |
| 83550 | <1% | 46 | $56.37 | |
| 86592 | <1% | 13 | $53.57 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 21 | $48.06 |
| 89051 | <1% | 26 | $44.52 | |
| 83615 | <1% | 12 | $41.97 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 65 | $15.70 |
| 36416 | <1% | 32 | $15.59 | |
| 81002 | <1% | 13 | $8.88 | |
| 80069 | <1% | 39 | $7.52 | |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 13 | $0.00 |
| 0001A | 0% | 16 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 12 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 42 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTANDE, BRETT (EVP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Scripps Health | Encinitas, CA | $11.95M |
| Scripps Health | La Jolla, CA | $9.79M |
| Scripps Health | La Jolla, CA | $502K |
| Scripps Health | La Jolla, CA | $57K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.